Australia's Opyl gains most in 3-1/2 years on trial recruitment platform sale

Pathkey.AI

23/04/2024 01:58

** Shares of Australia's Opyl  OPL.AX  rise as much as 42.1%
to A$0.027, post their biggest intraday pct gain since Sept 2020
    ** The AI firms says it has entered into an agreement to
divest its clinical trial recruitment platform Opin to peer
Trial Screen
    ** Says divestment will help co to focus more on high-growth
ventures
    ** Co will retain a 20% stake in Opin due to its stake in
Trial Screen
    ** Stock hits highest since March 25
    ** Stock has fallen 32.1% this year, as of last close

 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))